Validation of Sensors for Long-term Non-Invasive Fetal Monitoring
Launched by UNIVERSITY OF MANCHESTER · Apr 23, 2025
Trial Information
Current as of June 27, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a new sensor designed to monitor the heartbeats and movements of babies during late pregnancy. The goal is to see if this sensor can provide accurate information about the health of the baby, particularly to identify if the baby is not getting enough oxygen. The sensor is non-invasive, meaning it can be placed on the mother's skin without any sticky attachments, which may allow for longer monitoring times. The trial involves two parts: the first will fine-tune the sensor with up to 24 women to ensure it works well without interference from movement or other devices, and the second will include up to 45 women to compare the sensor’s readings with current methods.
To participate, women must be at least 16 years old and have a healthy, single pregnancy after 28 weeks, with the baby’s weight being between the 10th and 90th percentiles. Unfortunately, those with certain fetal conditions, multiple pregnancies, or who cannot understand English will not be eligible. Participants can expect to wear the sensor for monitoring during their pregnancy, and their involvement will help in developing a new device for better fetal monitoring in the future.
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • Participants will be included if they have a non-anomalous singleton pregnancy after 28 weeks' gestation with an estimated fetal weight \>10th centile \< 90th centile. Participants will be 16 years or over in order that they can give independent consent.
- Exclusion Criteria:
- • Participants will be excluded if there are fetal anomalies (as defined by the NHS Fetal Anomaly Screening Programme - https://www.gov.uk/guidance/fetal-anomaly-screening-programme-overview), it is a multiple pregnancy, there is evidence of Fetal Growth Restriction (Estimated Fetal Weight \<10th centile) or if participants cannot speak or do not understand fluent English. Participants will not be able to participate if they are unable to give informed consent. Participants \<16 years of age will be excluded from this study.
About University Of Manchester
The University of Manchester is a leading research institution known for its commitment to advancing healthcare through innovative clinical trials. With a strong emphasis on multidisciplinary collaboration, the university leverages its extensive expertise in biomedical research and clinical practice to develop and evaluate new therapies and interventions. The institution is dedicated to improving patient outcomes and public health by conducting rigorous, ethically sound trials that adhere to the highest standards of scientific integrity. Through its state-of-the-art facilities and a robust network of healthcare partnerships, the University of Manchester actively contributes to the global body of medical knowledge and the translation of research findings into clinical applications.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Manchester, , United Kingdom
Patients applied
Trial Officials
Alexander Heazell, PhD
Principal Investigator
University of Manchester
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported